Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc. is listed today as Supernus Pharmaceuticals, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2011 | $30 M | No. 1 | $10 to $50 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Supernus Pharmaceuticals, Inc., its revenue in fiscal 2025 came from these product and service lines: Qelbree $304.65 million (42%), GOCOVRI $146.82 million (20%), Collaboration revenue (ZURZUVAE) $53 million (7%), APOKYN $47.77 million (7%), Trokendi XR $42.42 million (6%).
Annual report (SEC XBRL) · Dec 2025
Supernus Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2012).
SEC Form D · Feb 2012
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Feb 2012
Products and services#
No products or services of Supernus Pharmaceuticals Inc. are on record.
Investors#
6 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Abingworth Management LTD | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| Nea 11 GP, LLC | Other | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| Nea Partners 11 LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| New Enterprise Associates 11 LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| Orbimed Capital GP II LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 3 investors.
Largest shareholders today
Institutions holding Supernus Pharmaceuticals, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$429 M17.10%
- Vanguard Portfolio Management LLC$141 M5.64%
- State Street Corp$111 M4.41%
- Armistice Capital, LLC$110 M4.38%
- Vanguard Capital Management LLC$109 M4.33%
- Millennium Management LLC$85 M3.39%
- Dimensional Fund Advisors LP$79 M3.16%
- Rubric Capital Management LP$75 M2.99%
- Stephens Investment Management Group LLC$71 M2.81%
- Two Sigma Investments, LP$70 M2.79%
- Geode Capital Management, LLC$66 M2.63%
- Loomis Sayles & Co L P$62 M2.46%
- GW&K Investment Management, LLC$59 M2.36%
- Morgan Stanley$50 M2.01%
- Renaissance Technologies LLC$49 M1.94%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jack A. Khattar | Executive officer | Feb 2012 |
| Jones W. Bryan, Ph.D. | Executive officer | Feb 2012 |
| Padmanabh P. Bhatt, Ph.D. | Executive officer | Feb 2012 |
| Paolo P. Baroldi, M.D., Ph.D. | Executive officer | Feb 2012 |
| Russell P. Wilson | Executive officer | Feb 2012 |
| Tami T. Martin, R.N., Esq. | Executive officer | Feb 2012 |
| Charles W. Newhall, III | Director | Feb 2012 |
| Frederick M. Hudson | Director | Feb 2012 |
| Jack A. Khattar | Director | Feb 2012 |
| John M. Siebert | Director | Feb 2012 |
| M. James Barrett, Ph.D. | Director | Feb 2012 |
| Michael B. Sheffery, Ph.D. | Director | Feb 2012 |
| Michael James Bigham | Director | Feb 2012 |
| William A. Nuerge | Director | Feb 2012 |
Went public since 2012. Its SEC number is that of a company listed on a stock exchange.